title: GlaxoSmithKline responds to the consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
authors.forename: P
authors.initials: P
authors.lastname: Ambery
authors.forename: A R
authors.initials: AR
authors.lastname: Cobitz
mesh_terms: D000465:Algorithms; D002318:Cardiovascular Diseases / Q000453:epidemiology; D003245:Consensus Statements as Topic; D018849:Controlled Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D004345:Drug Industry; D005060:Europe; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects; D000077154:Rosiglitazone; D012955:Societies, Medical; D045162:Thiazolidinediones / Q000009:adverse effects; D014481:United States
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone